Quarterly ResultMay 7, 2026, 01:41 PM
Quoin Pharma Q1 Net Loss $(5.0)M; Going Concern Doubt Raised
AI Summary
Quoin Pharmaceuticals Ltd. reported a net loss of $(5.0) million for the first quarter of 2026, an increase from $(3.8) million in the prior year, alongside a significant decrease in cash and investments. The company explicitly stated substantial doubt about its ability to continue as a going concern, necessitating additional funding. Despite financial challenges, Quoin is advancing its clinical pipeline, with QRX003 entering pivotal registrational testing for Netherton Syndrome and QRX009 targeting an IND submission in Q3 2026. The accumulated deficit reached $76.0 million.
Key Highlights
- Net loss increased to $(4,997,735) in Q1 2026 from $(3,812,179) in Q1 2025.
- Cash and cash equivalents decreased to $3.1 million from $3.8 million at year-end 2025.
- Investments decreased to $10.9 million from $14.9 million at year-end 2025.
- Research and development expenses rose to $3,433,762 in Q1 2026 from $2,374,139 in Q1 2025.
- Accumulated deficit grew to $76.0 million at March 31, 2026.
- Company raised "substantial doubt" about its ability to continue as a going concern.
- QRX003 is entering pivotal registrational clinical testing for Netherton Syndrome.
- QRX009 IND submission targeted for Q3 2026 for an additional indication.